<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04883242</url>
  </required_header>
  <id_info>
    <org_study_id>RG1121154</org_study_id>
    <secondary_id>NCI-2021-03406</secondary_id>
    <secondary_id>10690</secondary_id>
    <nct_id>NCT04883242</nct_id>
  </id_info>
  <brief_title>Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone (Isa-KPd) for Patients With Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the effect of isatuximab, carfilzomib, pomalidomide, and&#xD;
      dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or&#xD;
      does not respond to treatment (refractory). Isatuximab is a monoclonal antibody that may&#xD;
      interfere with the ability of cancer cells to grow and spread. Carfilzomib may stop the&#xD;
      growth of cancer cells by blocking some of the proteins needed for cell growth. Chemotherapy&#xD;
      drugs, such as pomalidomide, work in different ways to stop the growth of cancer cells,&#xD;
      either by killing the cells, by stopping them from dividing, or by stopping them from&#xD;
      spreading. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response&#xD;
      and are used with other drugs in the treatment of some types of cancer. Giving isatuximab,&#xD;
      carfilzomib, pomalidomide, and dexamethasone may kill more cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:&#xD;
&#xD;
      INDUCTION: Patients receive isatuximab intravenously (IV) on days 1, 8, 15, and 22 of cycle 1&#xD;
      and days 1 and 15 of subsequent cycles carfilzomib IV over 30 minutes on days 1, 8, and 15,&#xD;
      pomalidomide orally (PO) once daily (QD) on days 1-21, and dexamethasone PO or IV on days&#xD;
      1,8, 15, and 22. Treatment repeats every 28 days for 6 cycles in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      MAINTENANCE: Patients receive isatuximab IV days 1 and 15, carfilzomib IV over 30 minutes on&#xD;
      days 1 and 15, pomalidomide PO QD on days 1-21, and dexamethasone PO or IV on days 1, 8, 15,&#xD;
      and 22. Cycles repeat every 28 days for up to 24 months in the absence of disease progression&#xD;
      or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 30 days, then for up to 5&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2028</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Up to 5 years post treatment</time_frame>
    <description>Responses will be based on the International Myeloma Working Group criteria for response in multiple myeloma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From first study drug administration to the first occurrence of disease progression or death from any cause, assessed up to 5 years</time_frame>
    <description>PFS will be calculated using assessments by investigators. Kaplan-Meier methodology will be used to estimate event-free curves and corresponding quartiles (including the median).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the first study drug administration to death from any cause, assessed up to 5 years</time_frame>
    <description>Kaplan-Meier methodology will be used to estimate the event-free curves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to 5 years post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 30 days post treatment</time_frame>
    <description>Will be measured by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of minimal residual disease negativity</measure>
    <time_frame>Up to 5 years post treatment</time_frame>
    <description>Measured by next-generation sequencing of immunoglobulin genes in the bone marrow.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Recurrent Plasma Cell Myeloma</condition>
  <condition>Refractory Plasma Cell Myeloma</condition>
  <arm_group>
    <arm_group_label>Treatment (isatuximab, carfilzomib, pomalidomide, steroid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INDUCTION: Patients receive isatuximab IV on days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of subsequent cycles carfilzomib IV over 30 minutes on days 1, 8, and 15, pomalidomide PO QD on days 1-21, and dexamethasone PO or IV on days 1,8, 15, and 22. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
MAINTENANCE: Patients receive isatuximab IV days 1 and 15, carfilzomib IV over 30 minutes on days 1 and 15, pomalidomide PO QD on days 1-21, and dexamethasone PO or IV on days 1, 8, 15, and 22. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (isatuximab, carfilzomib, pomalidomide, steroid)</arm_group_label>
    <other_name>Kyprolis</other_name>
    <other_name>PR-171</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>Treatment (isatuximab, carfilzomib, pomalidomide, steroid)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycadron</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decadron DP</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasone Intensol</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Dxevo</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hemady</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>TaperDex</other_name>
    <other_name>Visumetazone</other_name>
    <other_name>ZoDex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Isatuximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (isatuximab, carfilzomib, pomalidomide, steroid)</arm_group_label>
    <other_name>Hu 38SB19</other_name>
    <other_name>Isatuximab-irfc</other_name>
    <other_name>SAR 650984</other_name>
    <other_name>SAR650984</other_name>
    <other_name>Sarclisa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (isatuximab, carfilzomib, pomalidomide, steroid)</arm_group_label>
    <other_name>4-Aminothalidomide</other_name>
    <other_name>Actimid</other_name>
    <other_name>CC-4047</other_name>
    <other_name>Imnovid</other_name>
    <other_name>Pomalyst</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with relapsed or refractory multiple myeloma, with 1 to 3 therapies&#xD;
&#xD;
          -  Must have received prior lenalidomide therapy and progressed on either a&#xD;
             lenalidomide-containing regimen or lenalidomide maintenance (defined as a dose of&#xD;
             10-15 mg lenalidomide daily after induction regimen or maintenance)&#xD;
&#xD;
          -  Must have measurable disease, as defined by International Myeloma Working Group&#xD;
             criteria, having one or more of the following:&#xD;
&#xD;
               -  Serum M protein &gt;= 1.0 g/dL&#xD;
&#xD;
               -  Urine M protein &gt;= 200 mg/24 hours&#xD;
&#xD;
               -  Involved serum free light chain level &gt;= 10 mg/dL with abnormal kappa/lambda&#xD;
                  ratio&#xD;
&#xD;
               -  Measurable biopsy-proven plasmacytomas (&gt;= 1 lesion has a single diameter &gt;= 2cm)&#xD;
&#xD;
               -  Bone marrow plasma cells &gt;= 30%&#xD;
&#xD;
          -  Age 18 years and older, and have the capacity to give informed consent&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2&#xD;
&#xD;
          -  Subjects should have resolution of any toxicities from prior therapy to grade =&lt; 1 or&#xD;
             baseline prior to enrollment (with the exception of peripheral neuropathy)&#xD;
&#xD;
          -  Subjects are required to have grade =&lt; 2 peripheral neuropathy to enroll&#xD;
&#xD;
          -  Prior autologous stem cell transplant is allowed; patients must be &gt;= 6 months post-&#xD;
             autologous stem cell transplantation to enroll&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &gt;= 20 ml/min&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =&lt; 3 x upper limit&#xD;
             of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin =&lt; 2 x ULN&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1,000/uL&#xD;
&#xD;
          -  Platelets &gt;= 50,000/uL&#xD;
&#xD;
          -  Hemoglobin &gt;= 8 g/dL&#xD;
&#xD;
          -  Growth factor use or transfusions may be used to meet the eligibility requirement for&#xD;
             ANC, platelets, and hemoglobin&#xD;
&#xD;
          -  Female patients of childbearing potential and male patients must agree to use 2&#xD;
             effective forms of contraception or continuously abstain from heterosexual intercourse&#xD;
             during the period of therapy, and for 6 months after discontinuation of study&#xD;
             treatment for females and 3 months after discontinuation of study treatment for males&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of clinically significant cardiovascular disease, including congestive heart&#xD;
             failure New York Heart Association (NYHA) class 3-4, symptomatic ischemia, left&#xD;
             ventricular ejection fraction &lt; 40%, uncontrolled conduction abnormalities, myocardial&#xD;
             infarction in last 6 months&#xD;
&#xD;
          -  Uncontrolled hypertension as determined by the principal investigator (PI) or designee&#xD;
&#xD;
          -  Active plasma cell leukemia or systemic amyloid light-chain (AL) amyloidosis&#xD;
&#xD;
          -  History of another primary malignancy that has not been in remission for at least 1&#xD;
             year (with the exception of non-melanoma skin cancer, curatively treated localized&#xD;
             prostate cancer, curatively treated superficial bladder cancer and cervical carcinoma&#xD;
             in site on biopsy or a squamous intraepithelial lesion on papanicolaou [PAP] smear)&#xD;
&#xD;
          -  Active hepatitis B, hepatitis C at time of screening&#xD;
&#xD;
          -  Subjects with active uncontrolled infection&#xD;
&#xD;
          -  Concurrent use of other anticancer agents or experimental treatments&#xD;
&#xD;
          -  Treatment with anti-CD38 monoclonal antibody therapy in the last 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew J. Cowan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew J. Cowan</last_name>
    <phone>206.667.4551</phone>
    <email>ajcowan@seattlecca.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew J. Cowan</last_name>
      <phone>206-667-4551</phone>
      <email>ajcowan@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>Andrew J. Cowan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Ichthammol</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

